Head-to-head · Cost-Efficiency Index
EdgeRx vs Aspen
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
EdgeRx
Men who also want adjacent peptide, longevity, and hormone protocols (MICC, sermorelin, NAD+, PT-141) bundled with GLP-1 on one account.
Visit EdgeRxAspen
Cost-first shoppers who want wanting one flat price regardless of whether treatment ends up being semaglutide or tirzepatide, if willing to commit to 3 months.
Visit AspenThe verdict
EdgeRx and Aspen tie on the Cost-Efficiency Index at 74/100, so neither wins outright on the numbers. For most shoppers we'd start with EdgeRx (ranked #55, a hair above #57) — Men who also want adjacent peptide, longevity, and hormone protocols (MICC, sermorelin, NAD+, PT-141) bundled with GLP-1 on one account. But Aspen is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs EdgeRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | EdgeRx | Aspen |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 74/100 |
| Semaglutide / mo | $229/mo (once-weekly injectable) | $179/mo (all doses, compounded) |
| Tirzepatide / mo | $299/mo (once-weekly injectable) | $179/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $2,748 | $2,148 |
| Tirzepatide / yr (modeled) | $3,588 | $2,148 |
| Coverage | 46 states — excludes Arkansas, Indiana, Minnesota, South Carolina | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #55 | #57 |
EdgeRx
74/100Where the value is
- Named Chief Medical Advisor (Dr. John Starke, MD, ABEM board-certified) sets clinical/dosing standards
- Named compounding pharmacy — Strive Pharmacy, a 503A facility operating since 2018
- LegitScript certified, with a specific, named state-exclusion list rather than a vague coverage claim
The tradeoffs
- Men's-only positioning — explicitly not a fit for women readers
- Dr. Starke sets standards but does not personally prescribe; the actual prescribing pool is an unnamed pool of licensed physicians
Aspen
74/100Where the value is
- One transparent, dose-independent flat price ($179/mo) covers either the semaglutide or tirzepatide path, avoiding the tirzepatide surcharge most compounded competitors charge
- Price stated to be all-in: provider consultation, custom dosing, medication, and free delivery bundled with no listed add-on fees
- No insurance required, cash-pay simplicity
The tradeoffs
- The bold '$179/mo' headline omits its own fine-print condition — a 3-month commitment — visible only in small text directly beneath the price
- Almost nothing else is disclosed on the public site: no states-served list, no named medical director or prescriber, no named pharmacy, and no LegitScript certification found
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.